3 Unstoppable Stocks to Buy in 2025

As we approach 2025, investors are looking for stocks that can weather market volatility and deliver consistent growth. Three companies stand out as potential powerhouses in their respective sectors: Eli Lilly (LLY), Intuitive Surgical (ISRG), and Vertex Pharmaceuticals (VRTX). Let's dive into the reasons why these stocks are poised for success in the coming year.



Eli Lilly's stock has been on a tear, driven by the success of its GLP-1 drugs, Mounjaro and Zepbound. Mounjaro is a treatment for diabetes, while Zepbound is a recently approved weight loss drug. In the most recent quarter, these drugs combined for just under $4.4 billion in sales. With these drugs in the early innings of their growth, there's substantial room for Eli Lilly's sales and profits to rise in the years ahead. Zepbound's success is particularly notable, as it helped people lose an average of 26.6% of their body weight over an 84-week period in clinical trials. This game-changing drug is a significant driver of Eli Lilly's growth prospects.



Intuitive Surgical (ISRG)

Intuitive Surgical has a dominant position in the robotic surgery market, with nearly 17 million procedures performed to date with its da Vinci robotic surgical system. The company projects worldwide procedure growth of between 13% and 16% in 2025, reflecting some near-term challenges but a long-term opportunity that is bigger than ever. Around 2.68 million procedures were performed with Intuitive's da Vinci system last year, which is less than half of the market it could address with its current regulatory clearances and only 16.5% of the total addressable market. As populations age and the company's robotic technology improves, Intuitive Surgical is expected to capture much more of this market over the next few years.



Vertex Pharmaceuticals (VRTX)

Vertex Pharmaceuticals has a monopoly in the market for therapies that treat the underlying causes of cystic fibrosis (CF), a rare disease of the lungs. This dominance helps the company generate strong revenue and earnings. Vertex's pipeline has made tremendous progress, with the company earning approval for a newer, better CF medicine in December 2024. It also expects to receive its first indication for an investigational pain medicine later in 2025. Despite a setback with the investigational pain medicine, Vertex Pharmaceuticals' strong financial performance and pipeline progress make it an unstoppable stock in 2025.



In conclusion, Eli Lilly, Intuitive Surgical, and Vertex Pharmaceuticals are three unstoppable stocks to consider in 2025. Their strong growth prospects, dominant market positions, and promising pipelines make them attractive investments for long-term growth. However, it is essential to remember that this article is a starting point for further investigation, and individual investors should conduct their own research or consult with a financial advisor before making any investment decisions.